Larimar Therapeutics announced an investor event on Monday, June 29, 2026 at 7:00 a.m. to provide updates on its Nomlabofusp program for Friedreich's ataxia. The item is a routine corporate update with no clinical data, financial guidance, or regulatory decision disclosed in the article. Market impact is likely minimal.
Larimar Therapeutics announced an investor event on Monday, June 29, 2026 at 7:00 a.m. to provide updates on its Nomlabofusp program for Friedreich's ataxia. The item is a routine corporate update with no clinical data, financial guidance, or regulatory decision disclosed in the article. Market impact is likely minimal.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.12
Ticker Sentiment
